HER2-POSITIVE BREAST CANCER

This study tests a personalized approach for people with HER2+ metastatic breast cancer. Doctors use a blood test (ctDNA) and scans to decide when to increase or decrease treatments, combined with local therapies and brain-sparing prevention. The goal is to achieve long-lasting r…

This study tests a drug called trastuzumab-deruxtecan (T-DXd) in people with HER2-positive breast cancer that has spread to 1-5 distant spots (oligo-metastatic). The goal is to shrink or eliminate all cancer with a year of treatment, including local therapies like radiation or su…

This early-phase trial tests an investigational vaccine designed to teach the immune system to recognize and attack HER2-positive breast cancer cells. The study includes 36 adults with locally advanced HER2-positive breast cancer. The main goals are to check the vaccine's safety …

This phase 3 trial tests whether a new drug, TQB2102, works better than the standard TCbHP regimen for shrinking HER2-positive breast tumors before surgery. About 544 participants will receive either treatment and then have their tumors assessed for complete response. The goal is…

This study tests a new drug called BL-M07D1, given with or without another drug (pertuzumab), compared to standard chemotherapy for HER2-positive breast cancer before surgery. The goal is to see if the new combination can eliminate more cancer cells by the time of surgery. About …

This early-phase study tests two drugs, palbociclib and avelumab, together for people with a specific type of advanced breast cancer (AR+ triple-negative). The main goals are to find the safest doses and see if the combination can shrink tumors. About 45 participants with advance…

This study tests whether a heart medication called nebivolol can prevent heart damage caused by trastuzumab, a common breast cancer treatment. Researchers will give 56 women with HER2-positive breast cancer either nebivolol or a placebo alongside their cancer therapy. The goal is…

This phase 3 trial tests whether a new drug, BL-M07D1, works better than the current standard (T-DM1) for people with HER2-positive breast cancer that still has invasive cancer after initial chemotherapy. About 1450 women aged 18-75 will be randomly assigned to receive one of the…

This early-phase trial tests an experimental drug called IAM1363 in people with advanced cancers that have HER2 alterations. The study aims to find a safe dose and see if the drug can shrink tumors, including those that have spread to the brain. About 383 adults whose cancer has …

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This phase 3 trial tests a new drug called IBI354, given with or without another drug (pertuzumab), against the current standard treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The study aims to see if the new combination helps de…

This study will follow 800 Chinese adults with advanced HER2-positive or HER2-low breast cancer who are taking trastuzumab deruxtecan (T-DXd). Researchers will track how long the drug keeps the cancer from getting worse and note any side effects. The goal is to see how well the t…

This study is looking at how well the drug trastuzumab deruxtecan works in Russian patients with advanced HER2-positive breast cancer that cannot be removed by surgery or has spread. Researchers will review medical records from 60 patients who have already received the drug to se…

This early-phase study tests whether giving specially grown immune cells (T cells) after a vaccine and two drugs is safe for people with advanced HER2-positive breast cancer. The treatment aims to help the body fight the cancer more effectively. About 28 participants will receive…

This study is for women with a certain type of breast cancer (HER2-positive, hormone receptor-positive) who still have small amounts of cancer after initial treatment. It compares two drug combinations to see which works better at preventing the cancer from coming back. About 300…

This study tests whether giving a combination of three drugs (neratinib, an aromatase inhibitor, and trastuzumab) for 24 weeks before surgery can eliminate all signs of cancer in the breast tissue of people with ER-positive, HER2-positive breast cancer. About 30 postmenopausal wo…

This study tests whether adding surgery and targeted radiation to the usual treatment can help people with HER2-positive breast cancer that has spread to a few other body parts (up to 5 spots). About 178 adults will be randomly assigned to get either standard care alone or standa…

This study tests a new treatment using specially engineered immune cells (CAR-NK cells) to fight advanced breast cancer. About 60 adults with HER2-positive or triple-negative breast cancer that has spread or cannot be removed will receive cells tailored to their tumor's markers. …

This study tests a new drug (RO7771950) combined with two standard treatments for people with advanced HER2-positive breast cancer that has spread or cannot be removed. The new drug is designed to reach the brain, which is important because this cancer often spreads there. About …

This study tests if radiation therapy followed by two targeted drugs (trastuzumab and pertuzumab) given directly into the spinal fluid is safe and helps people with HER2+ breast cancer that has spread to the lining of the brain and spinal cord (leptomeningeal disease). About 39 p…

This study is for people with early-stage (stage I) HER2-positive breast cancer who have had surgery. It compares two treatment plans: one uses the drug T-DM1 followed by trastuzumab, and the other uses paclitaxel plus trastuzumab. The goal is to see which approach causes fewer s…

This study tests whether two drugs, trastuzumab deruxtecan and durvalumab, can safely shrink or eliminate tumors in people with stage III inflammatory breast cancer that has a protein called HER2. About 63 participants will receive the drugs before surgery. The main goal is to se…

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target specific markers on breast cancer cells. It is for people with advanced HER2-positive or triple-negative breast cancer who have not responded to standard therapies. The goal is to se…

This study is for Nigerian women with a specific type of breast cancer called HER2-positive. Doctors want to see if giving a combination of targeted drugs before and after surgery can destroy the cancer completely. About 74 women will receive the treatment, and researchers will c…

This study tests whether adding a special vaccine (dendritic cell vaccine) to standard chemotherapy and targeted therapy can help people with HER2-positive breast cancer. About 53 participants will receive the vaccine alongside standard treatment before surgery. The goal is to se…

This study looks at how well a drug called trastuzumab-rezetecan works and how safe it is for people with HER2-positive or HER2-low breast cancer. Researchers will follow 300 patients who are already getting or will get this drug as part of their normal care. The goal is to see r…

This study tests whether adding the drug zanidatamab to standard chemotherapy can completely eliminate cancer in the breast and armpit before surgery in people with early-stage HER2-positive breast cancer. About 125 adults with stage II or III disease will receive the combination…

This study tests whether combining targeted drugs (tucatinib, trastuzumab, and capecitabine) with brain or spinal radiation is safe and effective for people with HER2-positive breast cancer that has spread to the lining of the brain or spinal cord (leptomeningeal disease). About …

This study tests a new, non-invasive imaging device that uses light to monitor how breast tumors respond to chemotherapy. Researchers want to see if it can accurately predict when the cancer has been completely eliminated (called a complete pathological response). The study invol…

This study tests if a special mammogram with contrast dye can predict whether breast cancer has been completely eliminated by chemotherapy, just as well as an MRI does. About 30 women with locally advanced breast cancer will get 1-2 of these mammograms during or after chemo, befo…

This study tests whether a diagnostic test called HER2DX can help doctors choose the best treatment for people with early-stage HER2-positive breast cancer. About 304 participants will be split into two groups: one gets standard treatment without the test results, and the other g…

This study tests whether taking probiotics can help prevent severe diarrhea in women with HER2-positive breast cancer who are taking the drug Neratinib. About 308 participants will be randomly assigned to receive either probiotics or a placebo, along with standard diarrhea preven…

This study examines tumor tissue from 10 HER2-positive breast cancer patients who had residual cancer after standard chemotherapy and trastuzumab. By comparing samples taken before and after treatment, researchers aim to identify cellular changes and interactions that may explain…

This study aims to match breast cancer patients with the most effective experimental drugs based on their tumor's unique features. Up to 5,000 participants will receive standard chemotherapy plus an experimental agent before surgery. Researchers will use MRI scans, tissue, and bl…

This study looks at whether a blood test that measures circulating tumor DNA (ctDNA) can help predict how well breast cancer responds to chemotherapy before surgery. Researchers will take blood samples from 125 women with stage II or III breast cancer before, during, and after tr…

This study is testing whether routine brain MRI scans can detect breast cancer that has spread to the brain in patients with certain types of advanced breast cancer. Researchers will follow 214 participants over time to see if early detection improves quality of life and reduces …

This study is testing whether a special whole-body MRI (DWB-MRI) can detect the return or spread of breast cancer earlier than standard methods. It involves 145 people with high-risk breast cancer types (HER2+ or triple-negative) who have had surgery. The goal is to see if earlie…

This study looks at whether regular brain MRIs can find cancer that has spread to the brain in people with stage IV breast cancer who have no brain symptoms. About 170 participants will get a screening brain MRI at the start and again at 6 months or when their cancer first progre…